Arteris, INC Form 4 insider transactions

Arteris, Inc. Chief Operating Officer Laurent R. Moll received a grant of 37,553 restricted stock units, aligning executive interests with shareholder value.

Arteris, Inc. CFO Nicholas B. Hawkins was granted 41,217 restricted stock units, vesting quarterly starting April 1, 2026, under a Rule 10b5-1 plan.

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, was granted 32,385 restricted stock units, vesting quarterly starting April 1, 2026.

Arteris, Inc. President and CEO Charles Janac disclosed an acquisition of restricted stock units and a gift of common stock.

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., sold a total of 50,000 shares of common stock in pre-planned transactions.

Arteris, Inc. President and CEO, Janac K. Charles, reported the sale of common stock totaling 50,000 shares under a Rule 10b5-1 trading plan.

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, exercised options and sold 5,000 shares of common stock for a significant gain under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. President and CEO, Janac K Charles, sold 17,884 shares of common stock for approximately $17.84 per share under a pre-arranged 10b5-1 trading plan.

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported the sale of 17,884 common shares at a weighted average price of $17.8357 per share, executed under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. President and CEO, Janac K Charles, sold 2,116 shares of common stock for $17.7901 per share under a pre-arranged 10b5-1 trading plan.

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported the sale of 2,116 shares of common stock at a weighted average price of $17.7901 per share.

Arteris, Inc. President and CEO, K. Charles Janac, sold 50,000 shares of common stock on January 8, 2026, through a pre-arranged 10b5-1 trading plan.

Bayview Legacy, LLC, a 10% owner and entity controlled by a director, reported the sale of 50,000 shares of Arteris, Inc. common stock under a 10b5-1 plan.

Arteris, Inc.'s VP and CFO, Nicholas B. Hawkins, sold 5,836 shares of common stock for a weighted average price of $17.272 per share under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. President and CEO, K. Charles Janac, reported the sale of 11,145 shares of common stock for approximately $188,380 under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Chief Operating Officer Laurent R. Moll reported the sale of 1,420 shares of common stock at $16.23 per share, executed under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Joachim Kunkel acquired 910 shares of common stock as fully vested restricted stock, representing deferred retainer fees.

Arteris VP and General Counsel, Paul L. Alpern, executed a planned sale of company stock following option exercise in early 2026.

Arteris, Inc. President and CEO, Charles K. Janac, sold 7,823 shares of common stock on January 2, 2026, to cover tax liabilities from restricted stock unit releases.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, sold common stock on January 2, 2026, to cover tax liabilities from restricted stock unit releases.

Arteris, Inc.'s VP and CFO, Nicholas B. Hawkins, sold common stock to cover tax liabilities from restricted stock unit vesting, while also acquiring shares through an employee plan.

Arteris VP and General Counsel Paul L. Alpern reported the sale of common stock, partially to cover tax liabilities and partially under a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, sold 17,937 shares of common stock for a weighted average price of $18.9615 per share under a pre-arranged trading plan.

Arteris Director Antonio J. Viana sold 20,000 shares of common stock for approximately $18.01 per share under a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold 721 shares of common stock for $17.56 per share under a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, sold a total of 35,137 shares of common stock in early December 2025 under a pre-arranged 10b5-1 trading plan.

Bayview Legacy, a 10% owner of Arteris Inc., reported sales of 130,000 common shares totaling approximately $2.29 million under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. President and CEO, Janac K. Charles, reported the sale of 130,000 shares of common stock in early December 2025 through a pre-arranged 10b5-1 trading plan.

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., sold 40,000 shares of common stock for approximately $16.46 per share under a pre-arranged 10b5-1 trading plan.

Arteris Inc.'s VP and General Counsel, Paul L. Alpern, exercised options and subsequently sold 7,500 shares of common stock under a pre-arranged 10b5-1 trading plan.